Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Regeneron Pharmaceuticals Inc
Gross Profit
Regeneron Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Moderna Inc
NASDAQ:MRNA
|
Gross Profit
$1.2B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
See Also
What is Regeneron Pharmaceuticals Inc's Gross Profit?
Gross Profit
11.3B
USD
Based on the financial report for Mar 31, 2024, Regeneron Pharmaceuticals Inc's Gross Profit amounts to 11.3B USD.
What is Regeneron Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
18%
Over the last year, the Gross Profit growth was 5%. The average annual Gross Profit growth rates for Regeneron Pharmaceuticals Inc have been 12% over the past three years , 13% over the past five years , and 18% over the past ten years .